For Veloxis Pharmaceuticals Inc.
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com
As a small but public company, the extern ship will provide a wide breadth of projects related to:
Reviewing and drafting contracts
Researching healthcare and corporate law issues as needed
Assisting with Nasdaq OMX compliance
Drafting and reviewing internal policies
Assisting with Corporate Governance activities
Assisting with management of intellectual property
This externship would be perfect for someone who is interested in learning how a corporate legal department works as well as anyone interested in international pharmaceuticals.
It would be helpful (but not required) if the student had taken Business Organizations, Health Law, Intellectual Property or other classes that touch on aspects of corporate law. Students do not need to be certified under the student practice rules for this externship.